What you can reduce is volume: the total number of sets and reps per session and per week
AOD 9604 is typically injected into the subcutaneous fat of the abdomen, and some users report targeted fat reduction in that area
The key considerations include: The stage and severity of liver disease simple steatosis versus NASH, fibrosis, or cirrhosis Overall liver function as assessed through blood tests and clinical evaluation Concurrent chronic alcohol misuse which significantly increases hepatotoxicity risk, particularly in those who are fasting or malnourished Other medications being taken that may affect liver metabolism, including enzyme-inducing drugs (such as carbamazepine, rifampicin, or St John's wort) Adherence to recommended dosing never exceeding maximum daily limits Patients with known fatty liver disease should discuss paracetamol use with their GP or hepatologist, who can assess individual risk factors and provide personalised guidance
its a natural consequence of weight loss itself
Pu, S.-Y., Huang, Y.-L., Pu, C.-M., Kang, Y.-N., Hoang, K
New England Journal of Medicine (2025) The REDEFINE 2 Phase 3 trial evaluated CagriSema in 1,206 adults with overweight or obesity and type 2 diabetes in a 68-week, double-blind, placebo-controlled design
